Shares of Kiora Pharmaceuticals Inc. (KPRX) Rise to a New 52-Week High

Kiora Pharmaceuticals Inc. (NASDAQ:KPRX) traded today at a new 52-week high of $6.65. Approximately 147,000 shares have changed hands today, as compared to an average 30-day volume of 19 million shares.

Kiora Pharmaceuticals Inc. (NASDAQ:KPRX) has potential upside of 28.4% based on a current price of $6.15 and analysts’ consensus price target of $7.90.

Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. The products pipeline of the company includes KIO-101, KIO-201, KIO-301, and KIO-102.

Over the past year, Kiora Pharmaceuticals Inc. has traded in a range of $0.12 to $6.65 and is now at $6.15, 4,962% above that low.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.